ARS Pharmaceuticals, Inc.
neffy is proving real demand, but at $6.07 the stock already discounts a meaningful rebound while the next leg still hinges on payer friction easing fast enough to close a very large profitability gap.
SPRY is no longer a binary launch concept. The product is in market, revenue is real, and the demand curve is credible. Q1 2026 total revenue reached $22.7M, with $17.5M from U.S. neffy net product revenue, prescription volume was 3x YoY, and the user base rose to about 120,000 after adding 29,500 patients in the quarter. That matters because the market is not debating whether neffy works commercially at all anymore. It is debating how efficiently that demand converts into durable, profitable revenue.
That is the crux of the stock at $6.07. Commercial access has improved meaningfully, with ~90% coverage and 57% of covered lives already free of prior authorization, but payer friction still shows up in an abandonment rate of 22% to 23%. Management is saying the right things about the second half, and CFO Kathleen Scott said, "As access improves and pending the outcome of the CVS Caremark process, we would expect more consistent prescription capture and improved revenue through the second half of the year." The problem is that this is still a company with -$0.06B of Q1 EBITDA, $72.2M of SG&A, and a cash breakeven target only by mid-2027. That leaves limited room for another stumble.
The valuation is not stretched on sales, at 5.93x P/S versus a peer average of 8.1x, but this discount is deserved until the business proves better conversion economics. There is no useful P/E support because EPS remains negative, and FY2025 operating margin was -27.9%. The stock being 61.6% below its 52-week high makes the setup less dangerous than it was, but deep drawdowns alone are not an investment case.
The case depends on three things. First, CVS/Caremark prior-authorization removal has to show up in actual script capture. Second, gross-to-net has to trend from the current low to mid-50% range toward the long-term ~50% target. Third, management has to start rebuilding credibility after 5 misses in the last 8 quarters. If those three line up, the equity can recover sharply because short interest is extreme. If they do not, the stock can stay cheap for a long time. That balance supports a firm HOLD, not a chase or a capitulation sell, ahead of earnings.
PA friction falls sharply, 2H prescription capture accelerates, and investors start underwriting a cleaner 2027 profitability path.
neffy adoption grows through 2H, but margin improvement remains slow enough that valuation stays anchored near the engine target.
CVS/Caremark changes underdeliver, abandonment stays near 22% to 23%, and cash breakeven slips beyond mid-2027.
Quant call (HOLD) diverges from analyst consensus (Strong Buy: 2 buy / 0 hold / 0 sell) — resolve explicitly.
The single greatest edge an investor can have is a long-term orientation.
Forward earnings power still matters more than trailing losses here, and the issue is not whether neffy can grow, but whether gross-to-net can move from the low to mid-50% range toward the ~50% steady-state target quickly enough to support a real 2027 earnings ramp. Trailing P/E is not meaningful because EPS is negative, so the right frame is that today’s 5.93x sales already assumes a viable specialty-pharma commercialization path, while peer P/E comparisons do little work in a loss-making biotech. The moat is better now than at launch because neffy has first-mover commercial traction, broadening coverage, and more than 28,000 HCPs who have prescribed it, but over 3 to 5 years durability will depend on payer acceptance and habit formation more than on AI. AI is mostly neutral here, useful at the margin for targeting prescribers and reimbursement workflow, but not a thesis driver; regulation and formulary access are far more important than technology disruption.
- CVS/Caremark PA removal is the key swing factor, with management targeting a July 1 effective date and saying 2H revenue should improve as access improves.
- Commercial coverage reached ~90% by Q1, with 57% of covered lives already without prior authorization, supporting better prescription conversion if denial friction falls.
- Profitability remains distant, with Q1 EBITDA of -$0.06B on $22.7M revenue, SG&A of $72.2M, and cash flow breakeven guided for before mid-2027.
- $22.7M of Q1 revenue, including $17.5M U.S. neffy net product revenue, shows commercialization is no longer theoretical.
- Prescription demand is building, with neffy prescription volume at 3x YoY, 29,500 patients added in Q1, and the U.S. user base reaching about 120,000.
- Access has improved versus launch expectations, with commercial coverage at ~90% by Q1 versus the 2024 Q3 target of more than 80% within 1 year.
- The stock is already deeply de-rated, sitting 61.6% below the 52-week high and 31.1% below the 200-day average, which limits valuation euphoria risk if 2H execution improves.
- The income statement is still weak, with FY2025 operating margin of -27.9%, FY2025 EPS of -$1.74, and Q1 2026 EBITDA margin of -254.8%.
- Near-term growth still depends heavily on one payer event, because management explicitly tied better 2H revenue to the pending CVS/Caremark process.
- Category friction remains material, with abandonment still in the 22% to 23% range and denied claims still blocking conversion.
- Sentiment and technicals remain damaged, with 33.26% short interest, 10.8 days-to-cover, a -21.58% 1-month move, and multiple securities class-action notices in the last two days.
| Metric | Value | Context |
|---|---|---|
| Current price | $6.07 | Reference price for target comparison |
| Price target | $6.02 | -0.9% vs current, High confidence, basis: sales_quality_blend |
| Quant baseline call | HOLD | High conviction |
| FY2025 revenue | $0.1B | 20564.3% YoY growth from launch commercialization |
| FY2025 EPS | -$1.74 | -66.0% YoY |
| FY2025 operating margin | -27.9% | Worse than prior FY -3.5% |
| Valuation | P/S 5.93, P/B 9.57, P/E N/A | P/S below peer avg 8.1, P/E not meaningful on losses |
| Balance sheet | Debt/Equity 1.57, Current ratio 4.94, Total debt $0.1B | Liquidity is solid, leverage is notable for a loss-making biotech |
| Q1 2026 operating snapshot | $22.7M revenue, EBITDA -$0.06B | EBITDA margin -254.8% |
| Commercial access | ~90% coverage, 57% without PA | Core variable for 2H script conversion |
| Price action | -61.6% vs 52-week high, -31.1% vs 200-day average | Stock is heavily de-rated |
| Short interest | 33.26% | 21,451,536 shares, 10.8 days-to-cover |
The biggest risk is that CVS/Caremark PA removal and broader access gains fail to materially reduce the 22% to 23% abandonment rate, leaving ARS stuck with heavy SG&A and delaying the guided mid-2027 cash breakeven path.
The next catalyst is earnings on August 13, 2026, especially any proof that post-July access changes are lifting capture rates and narrowing losses.
Ownership is concentrated, with the top three institutions holding 74.0%, led by specialized healthcare investors including OrbiMed, Rubric, and Deerfield, which signals informed sponsorship but can amplify volatility when the thesis breaks. Short interest is very high at 33.26%, or 21.45M shares, with 10.8 days-to-cover, so the stock has squeeze potential if the August print shows a clean post-access acceleration. Options positioning is reported as positive gamma in the front end, which can dampen some near-term volatility, but with the stock still 61.6% below its 52-week high, sentiment remains fragile rather than complacent.
Core commercial engine, driven by prescription volume growth and payer access expansion.
Included a $5M ALK milestone, with $2.5M recognized as collaboration revenue, so this is less durable than product revenue.
Management discussed U.S. neffy commercialization in detail; current-period geographic breakout beyond U.S. was not provided.
Q1 revenue grew, but the key swing factor is CVS PA removal heading into back-to-school.
Management has executed well on access ramp, but less well on the near-term P&L. On the 2024 Q3 call, the company said it was on track for 60% commercial coverage within six months and more than 80% within one year; by Q1 2026 it had reached ~90%, so that target was met and exceeded. The 2024 Q3 gross-to-net expectation was around 50%, while 2026 guidance is still low to mid-50% with a long-term target of approximately 50%, which means that piece has progressed more slowly than hoped. The early launch narrative also proved real, moving from just $0.6M of one-week neffy revenue in 2024 Q3 to $17.5M U.S. net product revenue in Q1 2026, but earnings credibility is mixed because the last 8 reported quarters included 5 misses, 2 in-line results, and only 1 major beat. On the pipeline side, the 2024 Q3 call pointed to CSU Phase 2b data by the beginning of 2026 at the latest, and no update is provided here confirming delivery, so that timeline should be treated as at least uncertain.
In the first quarter, we generated $22.7 million in total revenue. This includes $17.5 million in U.S. net product revenue for neffy, which represents 3x the volume of neffy prescriptions year-over-year and more than double the revenue.
As access improves and pending the outcome of the CVS Caremark process, we would expect more consistent prescription capture and improved revenue through the second half of the year.
We continue to expect our overall SG&A run rate for 2026 to be slightly higher than the run rate for the second half of 2025.
We are expecting to see meaningful market share growth and our projections at least are that we would be on track with current consensus even without Caremark. So Caremark would add to that, of course.
In our projections, we will get to cash breakeven by mid-2027.
The moat is narrow but improving. neffy’s advantage is product format plus early commercialization scale, with ~90% commercial coverage, 28,000+ HCPs having prescribed it, and about half of those showing repeat use, which starts to build prescriber habit and patient familiarity. Durability is still not fully proven because payer behavior, gross-to-net, and category abandonment are more important than pure product differentiation, so returns are not yet protected the way they would be for a mature specialty franchise.
Capital allocation is still about funding launch and access, not returning capital. The company reported FCF of $0.0B, capex of $0.0B, buybacks of $0.0B, and dividends of $0.0B, while management expanded the sales force to 148 in May through resource reallocation rather than a major spend step-up. That is reasonably disciplined for a commercial-stage biotech, but with -$0.06B Q1 EBITDA and breakeven not expected until mid-2027, balance-sheet preservation remains the real priority.
Rated HOLD, High conviction. The business has improved enough that a bearish call would ignore real commercialization progress, but a bullish call at $6.07 would also ignore that the engine target is $6.02, losses remain large, and the next step still depends on payer friction easing quickly. This is a show-me story into the August 13 earnings report. A move to BUY would require clear evidence that post-access script capture is accelerating and that the mid-2027 breakeven path is getting more credible, not less. A move to SELL would require evidence that coverage gains are failing to translate into revenue efficiency.
≣ Full research note tap to expand
Executive Summary
HOLD, High conviction. Rated HOLD, High conviction. ARS has moved from launch story to commercial proof point, with Q1 2026 revenue of $22.7M, U.S. neffy net product revenue of $17.5M, and commercial coverage at ~90%, but the business still ran at -$0.06B EBITDA and management does not expect cash breakeven until mid-2027. The setup is better than the recent share-price collapse implies, yet the quant base case of $6.02 is hard to dismiss because near-term upside still depends on CVS/Caremark prior-authorization removal and 2H capture improving materially.
Investment Thesis
SPRY is no longer a binary launch concept. The product is in market, revenue is real, and the demand curve is credible. Q1 2026 total revenue reached $22.7M, with $17.5M from U.S. neffy net product revenue, prescription volume was 3x YoY, and the user base rose to about 120,000 after adding 29,500 patients in the quarter. That matters because the market is not debating whether neffy works commercially at all anymore. It is debating how efficiently that demand converts into durable, profitable revenue.
That is the crux of the stock at $6.07. Commercial access has improved meaningfully, with ~90% coverage and 57% of covered lives already free of prior authorization, but payer friction still shows up in an abandonment rate of 22% to 23%. Management is saying the right things about the second half, and CFO Kathleen Scott said, "As access improves and pending the outcome of the CVS Caremark process, we would expect more consistent prescription capture and improved revenue through the second half of the year." The problem is that this is still a company with -$0.06B of Q1 EBITDA, $72.2M of SG&A, and a cash breakeven target only by mid-2027. That leaves limited room for another stumble.
The valuation is not stretched on sales, at 5.93x P/S versus a peer average of 8.1x, but this discount is deserved until the business proves better conversion economics. There is no useful P/E support because EPS remains negative, and FY2025 operating margin was -27.9%. The stock being 61.6% below its 52-week high makes the setup less dangerous than it was, but deep drawdowns alone are not an investment case.
The case depends on three things. First, CVS/Caremark prior-authorization removal has to show up in actual script capture. Second, gross-to-net has to trend from the current low to mid-50% range toward the long-term ~50% target. Third, management has to start rebuilding credibility after 5 misses in the last 8 quarters. If those three line up, the equity can recover sharply because short interest is extreme. If they do not, the stock can stay cheap for a long time. That balance supports a firm HOLD, not a chase or a capitulation sell, ahead of earnings.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $6.07 | Reference price for target comparison |
| Price target | $6.02 | -0.9% vs current, High confidence, basis: sales_quality_blend |
| Quant baseline call | HOLD | High conviction |
| FY2025 revenue | $0.1B | 20564.3% YoY growth from launch commercialization |
| FY2025 EPS | -$1.74 | -66.0% YoY |
| FY2025 operating margin | -27.9% | Worse than prior FY -3.5% |
| Valuation | P/S 5.93, P/B 9.57, P/E N/A | P/S below peer avg 8.1, P/E not meaningful on losses |
| Balance sheet | Debt/Equity 1.57, Current ratio 4.94, Total debt $0.1B | Liquidity is solid, leverage is notable for a loss-making biotech |
| Q1 2026 operating snapshot | $22.7M revenue, EBITDA -$0.06B | EBITDA margin -254.8% |
| Commercial access | ~90% coverage, 57% without PA | Core variable for 2H script conversion |
| Price action | -61.6% vs 52-week high, -31.1% vs 200-day average | Stock is heavily de-rated |
| Short interest | 33.26% | 21,451,536 shares, 10.8 days-to-cover |
Financial Strength
The balance sheet is adequate for now, not pristine. A 4.94 current ratio gives ARS time to execute, but Debt/Equity of 1.57 is meaningful for a business with negative EPS, negative operating margin, and Q1 EBITDA of -$0.06B. Cash generation is not yet there, with FCF at $0.0B and breakeven still guided for mid-2027, so the financial read is that liquidity buys time, but not enough to excuse prolonged commercialization inefficiency. Margin trajectory is the main issue, because revenue is clearly scaling faster than profitability.
Competitive Position
The moat is narrow but improving. neffy’s advantage is product format plus early commercialization scale, with ~90% commercial coverage, 28,000+ HCPs having prescribed it, and about half of those showing repeat use, which starts to build prescriber habit and patient familiarity. Durability is still not fully proven because payer behavior, gross-to-net, and category abandonment are more important than pure product differentiation, so returns are not yet protected the way they would be for a mature specialty franchise.
Management & Guidance
Management guided to a slightly higher 2026 SG&A run rate versus 2H25, revenue weighted to 2H 2026, gross-to-net in the low to mid-50% range for 2026, a long-term steady-state gross-to-net of approximately 50%, majority unrestricted Medicaid coverage by early 2027, and cash flow breakeven before mid-2027. That guidance is plausible but not fully de-risked. Management deserves credit for beating its prior commercial coverage target, but the earnings record is mixed and the current outlook still leans heavily on CVS/Caremark and better claim conversion rather than on already-demonstrated margin leverage.
Segment Analysis
- U.S. neffy net product revenue ($17.5M of Q1 2026 revenue, about 77% of total): Core commercial engine, driven by prescription volume growth and payer access expansion.
- Collaboration and milestone revenue ($5.2M of Q1 2026 revenue, about 23% of total): Included a $5M ALK milestone, with $2.5M recognized as collaboration revenue, so this is less durable than product revenue.
- Geography (Primarily U.S. disclosed in current operating data): Management discussed U.S. neffy commercialization in detail; current-period geographic breakout beyond U.S. was not provided.
Capital Allocation
Capital allocation is still about funding launch and access, not returning capital. The company reported FCF of $0.0B, capex of $0.0B, buybacks of $0.0B, and dividends of $0.0B, while management expanded the sales force to 148 in May through resource reallocation rather than a major spend step-up. That is reasonably disciplined for a commercial-stage biotech, but with -$0.06B Q1 EBITDA and breakeven not expected until mid-2027, balance-sheet preservation remains the real priority.
Management Execution & Track Record
Management has executed well on access ramp, but less well on the near-term P&L. On the 2024 Q3 call, the company said it was on track for 60% commercial coverage within six months and more than 80% within one year; by Q1 2026 it had reached ~90%, so that target was met and exceeded. The 2024 Q3 gross-to-net expectation was around 50%, while 2026 guidance is still low to mid-50% with a long-term target of approximately 50%, which means that piece has progressed more slowly than hoped. The early launch narrative also proved real, moving from just $0.6M of one-week neffy revenue in 2024 Q3 to $17.5M U.S. net product revenue in Q1 2026, but earnings credibility is mixed because the last 8 reported quarters included 5 misses, 2 in-line results, and only 1 major beat. On the pipeline side, the 2024 Q3 call pointed to CSU Phase 2b data by the beginning of 2026 at the latest, and no update is provided here confirming delivery, so that timeline should be treated as at least uncertain.
Positioning & Flows
Ownership is concentrated, with the top three institutions holding 74.0%, led by specialized healthcare investors including OrbiMed, Rubric, and Deerfield, which signals informed sponsorship but can amplify volatility when the thesis breaks. Short interest is very high at 33.26%, or 21.45M shares, with 10.8 days-to-cover, so the stock has squeeze potential if the August print shows a clean post-access acceleration. Options positioning is reported as positive gamma in the front end, which can dampen some near-term volatility, but with the stock still 61.6% below its 52-week high, sentiment remains fragile rather than complacent.
Bull Case
- $22.7M of Q1 revenue, including $17.5M U.S. neffy net product revenue, shows commercialization is no longer theoretical.
- Prescription demand is building, with neffy prescription volume at 3x YoY, 29,500 patients added in Q1, and the U.S. user base reaching about 120,000.
- Access has improved versus launch expectations, with commercial coverage at ~90% by Q1 versus the 2024 Q3 target of more than 80% within 1 year.
- The stock is already deeply de-rated, sitting 61.6% below the 52-week high and 31.1% below the 200-day average, which limits valuation euphoria risk if 2H execution improves.
Bear Case
- The income statement is still weak, with FY2025 operating margin of -27.9%, FY2025 EPS of -$1.74, and Q1 2026 EBITDA margin of -254.8%.
- Near-term growth still depends heavily on one payer event, because management explicitly tied better 2H revenue to the pending CVS/Caremark process.
- Category friction remains material, with abandonment still in the 22% to 23% range and denied claims still blocking conversion.
- Sentiment and technicals remain damaged, with 33.26% short interest, 10.8 days-to-cover, a -21.58% 1-month move, and multiple securities class-action notices in the last two days.
Valuation & Price Target
Engine price target $6.02 (-0.9% vs current), High confidence.
- P/S Multiple: $6.17 (45% weight)
- Quality-adjusted: $5.68 (20% weight)
The HOLD rating matches the quant baseline and does not need a forced divergence. The engine’s $6.02 target versus the $6.07 stock price is consistent with a business that has clearly improved commercially, 5.93x P/S below the 8.1x peer average, but still carries only a 42/100 quality score, a 54/100 moderate risk score, negative earnings, and a stated cash breakeven date of mid-2027. Sell-side consensus sits at Strong Buy from only 2 firms, which is too thin and too optimistic to outweigh the hard evidence of repeated EPS misses and a still very unprofitable model.
Risk Assessment
Risk score 54/100 (Moderate). The biggest risk is that CVS/Caremark PA removal and broader access gains fail to materially reduce the 22% to 23% abandonment rate, leaving ARS stuck with heavy SG&A and delaying the guided mid-2027 cash breakeven path.
The Bottom Line
Rated HOLD, High conviction. The business has improved enough that a bearish call would ignore real commercialization progress, but a bullish call at $6.07 would also ignore that the engine target is $6.02, losses remain large, and the next step still depends on payer friction easing quickly. This is a show-me story into the August 13 earnings report. A move to BUY would require clear evidence that post-access script capture is accelerating and that the mid-2027 breakeven path is getting more credible, not less. A move to SELL would require evidence that coverage gains are failing to translate into revenue efficiency.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr